RECOMBINANT ANTIBODIES ASSOCIATED TO GANGLIOSIDES. THEIR USE INDIAGNOSIS AND TREATMENT OF TUMORS.

摘要

THE PRESENT INVENTION IS RELATED WITH THE FIELD OF THE BIOTECHNOLOGY AND MORE SPECIFICALLY WITH RECOMBINANT ANTIBODIES OBTAINED BY MEANS OF THE DNA RECOMBINANT TECHNOLOGY. MORE SPECIFICALLY THE INVENTION IS RELATED WITH MODIFIED ANTIBODIES WITH A REDUCED IMMUNOGENICITY WHEN INJECTED TO HUMAN WHILE PRESERVING THE ANTIGEN BINDING RECOGNITION PROPERTIES. SPECIFICALLY THE INVENTION DISCLOSES CHIMERIC AND HUMANIZED ANTIBODIES OBTAINED FROM THE MURINE MONOCLONAL ANTIBODY P3 (MAB P3) PRODUCED BY THE HYBRIDOMA CELL LINE WITH DEPOSIT NUMBER ECACC 94113026 AND ITS ANTI-IDIOTYPE MURINE MONOCLONAL ANTIBODY 1 E1 0 (MABAI 1E10) PRODUCED BY THE HYBRIDOMA CELL LINE WITH DEPOSIT NUMBER ECACC 97112901. THE HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODIES OF THE PRESENT INVENTION PRESERVE THE BIOLOGICAL FUNCTION OF SPECIFIC BINDING TO THE ANTIGEN OF THE MURINE ANTIBODY. THE PRESENT INVENTION IS ALSO RELATED WITH USE OF THE ANTIBODIES FOR THERAPEUTICAL AND DIAGNOSTIC PURPOSES.